Featured Recent Coverage

Press & Media

Dr. Weintraub's expertise has been featured across national media including television, podcasts, and leading health platforms. As a triple board-certified physician in endocrinology, internal medicine, and obesity medicine, he has contributed to peer-reviewed research and helped thousands of patients in New York City navigate complex endocrine conditions.

Dr. Weintraub is available for expert commentary on GLP-1 receptor agonists, obesity pharmacotherapy, diabetes care, metabolic health, and clinical endocrinology.

Contact for Media Inquiries

As Featured In

Showing all 42

Live Media Appearances

New York Post

This dangerous condition can sneak up on you – how GLP-1 drugs can help

January 2026

Discusses how GLP-1 medicines can treat prediabetes and prevent its progression to type 2 diabetes, framing early pharmacologic intervention as key to metabolic risk reduction.

Watch Video →

ClearView Convos

The emerging obesity landscape

December 2025

Discusses emerging obesity medicine landscape.

Watch on YouTube →

Downsized Podcast

Interview on weight management strategies

December 2025

Dr. Weintraub recaps his ObesityWeek podium presentation on GLP-1 discontinuation rates and weight change.

Listen →

Endocrine News Podcast

Compounded Obesity Medications

December 2025

Explores safety and efficacy concerns around compounded GLP-1 medications that became popular alternatives during brand-name shortages.

Listen →

Metabolic Care Today

Complex obesity care management

October 2025

Discusses clinical strategies for managing patients with complex obesity and how to tailor treatment to comorbidities for better outcomes.

Watch Video →

Metabolic Care Today

EASO treatment guidelines

October 2025

Discusses how the new European Association for the Study of Obesity (EASO) framework reshapes the way clinicians diagnose and treat obesity by moving beyond BMI.

Watch Video →

Sirius XM Doctor Radio

Interview on the Men's Health Show

September 2025

Metabolic Care Today

Orforglipron Phase 3 Data: Dr. Michael Weintraub Reviews ATTAIN-1 and ACHIEVE-1 Findings

August 2025

Reviews the ATTAIN-1 and ACHIEVE-1 Phase 3 findings for oral orforglipron in weight loss and type 2 diabetes.

Watch Interview →

CBS News

Can weight loss drugs curb more than appetite? What to know about research on other possible effects

August 2024

Advises using established medications for alcohol and smoking cessation before considering GLP-1 drugs off-label, cautioning "the jury's still out" on their other potential uses.

Read Article →

Diabetes Connections Type 2 Podcast

Navigating the Ozempic and Mounjaro shortage

June 2024

Discusses strategies for patients facing GLP-1 shortages, including start-and-stop tips and how to navigate supply disruptions.

Listen →

Sirius XM Doctor Radio

Interaction of thyroid disease, obesity and cardiovascular disease

January 26, 2024

Sirius XM Doctor Radio

Thyroid disease and relation with venous thromboembolism

January 5, 2024

The Blueprint Podcast

The obesity epidemic: Causes, solutions and the mindset for long-term weight loss

November 2023

Core Internal Medicine Podcast

Steroids

May 2023

Explains physiologic cortisol production and adrenal insufficiency risk stratification by dose and duration.

Listen →

Sirius XM Doctor Radio

Pharmacologic management of obesity

April 2023

Endocrine News Podcast

Obesity Pharmacotherapy

June 2022

Discusses five-year outcomes data on anti-obesity medications for long-term weight loss maintenance, based on research presented at the Endocrine Society annual meeting.

Listen →

Sirius XM Doctor Radio

Medical Grand Rounds

June 2022

Endocrine Society

Obesity pharmacotherapy

June 2022

News Article Interviews

Forbes

Wegovy 'HD' Dose Is Here — How To Find GLP-1 Medications And Compare Costs

April 2026

Comments on the new higher-dose Wegovy 7.2mg.

Read Article →

HCPLive

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

January 2026

Interviewed on research showing significant weight regain after GLP-1 discontinuation, reinforcing that obesity is a chronic condition requiring sustained treatment.

Read Article →

The Verge

The wellness wild west is back on its bullshit with unapproved weight loss drugs

January 2026

Cautions against unapproved compounded GLP-1 and retatrutide products sold through wellness channels, stressing safety and regulatory oversight.

Read Article →

Medscape

Over half regain weight after stopping GLP-1s

November 2025

Comments on data showing most patients regain substantial weight after stopping GLP-1 therapy, underscoring the need for continuous treatment strategies.

Read Article →

CNBC News

Eli Lilly pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial

September 2025

Comments on head-to-head Phase 3 data where Lilly's oral orforglipron outperformed Novo Nordisk's oral semaglutide in type 2 diabetes.

Read Article →

NBC News

FDA warns about unapproved thyroid pills

August 2025

Comments on FDA warnings about unapproved over-the-counter thyroid supplements and the risks they pose to patients.

Read Article →

STAT News

Eli Lilly's very bad day

August 2025

Emphasizes that insurance companies — not physicians — control patient access to GLP-1 drugs despite their proven effectiveness.

Read Article →

The Gut Punch

Why GLP-1 drugs are so expensive

March 2025

Comments on the affordability crisis around GLP-1 therapies and the systemic barriers patients face accessing effective treatment.

Read Article →

Medscape

'Vicious Cycle': Are there Benefits to 'Yo-Yo Dieting?'

January 2025

Weighs in on whether weight cycling yields any metabolic benefit and what it means for patients considering GLP-1 restart.

Read Article →

Medscape

Commission Issues 'Radical Overhaul' of Obesity Diagnosis

January 2025

Weighs in on the Lancet Commission's new framework redefining obesity diagnosis beyond BMI alone.

Read Article →

NBC News

Obesity dipped in U.S. last year for the first time in more than a decade

December 2024

Comments on the first U.S. obesity prevalence decline in over a decade, partly attributable to widespread GLP-1 use.

Read Article →

Medscape

How to manage patients on GLP-1s before surgery?

November 2024

Advises on perioperative GLP-1 management, including whether to hold medications before elective procedures.

Read Article →

Yahoo Finance

Weight-loss drug competition heats up with growing pill market

September 2024

Advocates that multiple weight-loss drug options are necessary because "no single patient responds the same way" — letting physicians better match medications to individual patients.

Read Article →

Medscape

Semaglutide bests liraglutide in long-term weight loss

September 2024

Reviews head-to-head data showing semaglutide's superior long-term weight loss versus liraglutide, and implications for prescribing choice.

Read Article →

Medscape

Will tirzepatide vials help patients? Endos weigh in

September 2024

Comments on whether Lilly's direct-to-patient tirzepatide vial offering will improve access to Zepbound for eligible patients.

Read Article →

TIME Magazine

The weight loss drug that can prevent diabetes

September 2024

Comments on tirzepatide's ability to prevent progression from prediabetes to type 2 diabetes, calling it a meaningful advance in diabetes prevention.

Read Article →

Gizmodo

The truth about Ozempic and muscle loss

June 2024

Explains that GLP-1 muscle loss is on par with diet or surgery — not unique to these drugs — and advises patients on adequate protein intake and resistance training.

Read Article →

Medscape

How are Endos handling weight-loss drug shortages?

March 2024

Describes strategies endocrinologists are using to navigate GLP-1 shortages, including dose adjustments and switching between agents.

Read Article →

Engineering

Effective anti-obesity medications make losing weight a big deal

September 2023

Reuters

US psychiatrists prescribe Wegovy to battle medication-induced weight gain

August 2023

Comments on the use of Wegovy to counter weight gain from psychiatric medications, and the collaborative care this requires.

Read Article →

Business Insider

Berberine is being called 'nature's Ozempic' - here's what the supplement actually does to your body

June 2023

Explains that berberine is not a legitimate substitute for GLP-1 therapies despite viral claims labeling it "nature's Ozempic."

Read Article →

Wired Magazine

A pill version of Ozempic is coming

May 2023

Discusses the arrival of oral semaglutide and what a pill formulation means for patient access to GLP-1 therapy.

Read Article →

Medscape

Does Ozempic cause hair loss?

May 2023

Explains that hair loss during rapid weight loss reflects the physiologic stress of caloric deficit, not a direct effect of semaglutide itself.

Read Article →

Public Good News

Understanding the Ozempic shortage and how to navigate it

March 2023

Recommends patients communicate with prescribers and pharmacists, try other pharmacy chains, ask about lower doses, or request alternative GLP-1 agonists when a preferred drug is unavailable.

Read Article →

Endocrine Society Virtual Writers Conference

The changing landscape of obesity care (Physician panelist)

February 2023

Clinical Advisor

Semaglutide and Tirzepatide: Top 5 things clinicians should know

March 2023

Summarizes the top five considerations for clinicians prescribing semaglutide and tirzepatide: dosing, side effects, monitoring, insurance navigation, and long-term adherence.

Read Article →